The latest health news highlights major biotech and pharmaceutical updates, including Septerna's market debut, Sanofi's ...

Recent health news highlights include high costs of weight-loss drugs like Wegovy, Septerna's strong Nasdaq debut, ...

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

The global vaccines market is poised for extraordinary growth, with projections indicating a Compound Annual Growth Rate (CAGR) of 6.6%. This anticipated expansion will elevate the market from its ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.